How much fat is necessary to optimize lumefantrine oral bioavailability?
BACKGROUND: Artemether-lumefantrine (AL) is the only fixed, artemisinin-based combination antimalarial drug which is registered internationally and deployed on a large scale. Absorption of the hydrophobic lipophilic lumefantrine component varies widely between individuals and is greatly increased b...
Κύριοι συγγραφείς: | Ashley, E, Stepniewska, K, Lindegårdh, N, Annerberg, A, Kham, A, Brockman, A, Singhasivanon, P, White, N, Nosten, F |
---|---|
Μορφή: | Journal article |
Γλώσσα: | English |
Έκδοση: |
2007
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.
ανά: Tarning, J, κ.ά.
Έκδοση: (2009) -
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria.
ανά: Ashley, E, κ.ά.
Έκδοση: (2007) -
Pharmacokinetic study of artemether-lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria
ανά: Ashley, E, κ.ά.
Έκδοση: (2007) -
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
ανά: Mcgready, R, κ.ά.
Έκδοση: (2006) -
The pharmacokinetics of artemether and lumefantrine in pregnant women with uncomplicated falciparum malaria.
ανά: McGready, R, κ.ά.
Έκδοση: (2009)